Rhumbline Advisers Genprex, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$3.11 - $4.87 $83,836 - $131,280	-26,957 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$3.66 - $7.67 $384 - $805	105 Added 0.39%	26,957 $116,000
Q4 2020 Feb 10, 2021	BUY	$3.03 - $5.51 $6,408 - $11,653	2,115 Added 8.55%	26,852 $111,000
Q3 2020 Nov 12, 2020	SELL	$2.9 - $4.29 $4,582 - $6,778	-1,580 Reduced 6.0%	24,737 $83,000
Q2 2020 Aug 13, 2020	BUY	$1.99 - $3.64 $52,370 - $95,793	26,317 New	26,317 $83,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.